

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Final Appraisal Determination

(when no ACD was issued)

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

|   |
|---|
| No equality issues were identified during the scoping process |
|---|

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|--|

|   |
|---|
| No potential equality issues have been identified in the evidence submitted |
|---|

- |  |
|--|
| 3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? |
|--|

|  |
|--|
| No potential equality issues have been identified by the Committee |
|--|

- |   |
|---|
| 4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups?<br>If so, what are the barriers to, or difficulties with, access for the |
|---|

|                 |
|-----------------|
| specific group? |
| No              |

|   |
|---|
| 5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? |
| No  |

|   |
|---|
| 6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality? |
| Not applicable  |

|   |
|---|
| 7. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where? |
| Not applicable  |

**Approved by Programme Director (name):** Meindert Boysen

.....

**Date:** 07/10/2015